#United States #sickle cell disease #Vascarta #Summit #Vasceptor

Vascarta's Pioneering Orphan Drug Designation

Vascarta Inc., a dedicated biopharmaceutical company, announced a major milestone today: its lead drug, Vasceptor® (VAS-101), has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of Sickle Cell Disease (SCD). This designation is crucial as it highlights the drug's potential to address a pressing medical need—treating a rare disease that impacts fewer than 200,000 patients in the U.S.

Understanding Orphan Drug Designation

This designation not only acknowledges the unique therapeutic potential of Vasceptor® but also provides the company with significant benefits. Upon approval, Vascarta is entitled to seven years of market exclusivity, tax credits for qualified clinical trials, and specific exemptions from FDA fees, all of which play a vital role in expediting the drug's availability to those in need.

Dr. Richard Prince, Vascarta’s CEO and President, expressed enthusiasm over the designation, stating, "This represents an essential regulatory milestone for Vascarta and emphasizes Vasceptor®'s capability to deliver safe and effective treatment for patients suffering from this debilitating disease." The company is committed to collaborating closely with the FDA to ensure that Vasceptor® reaches the market swiftly.

The Science Behind Vasceptor®

Developed specifically by Vascarta, Vasceptor® is a patented topical formulation of curcumin, leveraging advanced transdermal technology to combat the limited effectiveness often associated with oral curcumin supplements. Current studies, including those published in PNAS Nexus, suggest that Vasceptor® may not only alleviate chronic pain related to SCD but also stabilize red blood cells and reduce inflammation, pivotal factors that contribute to the overall challenges faced by those with the disease.

In preclinical studies, the findings were promising, showing significant pain relief through a unique process targeting red blood cell instability, neuro-inflammation, and vascular inflammation. Dr. Joel Friedman, Vascarta's Scientific Founder and esteemed professor at the Albert Einstein College of Medicine, remarked on the positive implications of these studies, as Vasceptor® aims to offer a therapy that could potentially alleviate many of the clinical issues faced by SCD patients.

The Burden of Sickle Cell Disease

Sickle Cell Disease profoundly impacts the quality of life for those affected. It is the most prevalent inherited genetic disorder primarily within African American and non-Hispanic Black populations in the U.S. The disease can lead to severe complications, such as anemia, intense pain crises, risk of stroke, and organ damage. Despite recent advancements in treatment options, many existing therapies fail to adequately manage pain and come with a range of adverse side effects.

With an estimated 175,000 cases in the United States alone and a significantly reduced life expectancy for those affected, there is an urgent need for therapies that not only enhance patient outcomes but also minimize the reliance on blood transfusions and harmful, chronic pain medications. Vascarta's focus on accessible and effective treatments aligns with the pressing needs of SCD patients.

Looking Ahead

As Vascarta approaches the next phases of clinical trials for Vasceptor®, the biopharmaceutical company remains dedicated to innovating solutions for those impacted by inflammatory and genetic disorders. Vascarta Inc. is positioned at the forefront of mitigating the impact of SCD and enhancing the lives of patients who have long been underserved in their quest for optimal health and quality of life.

For more information about Vascarta and its initiatives or to inquire about media interests, please reach out to Dr. Richard Prince or David Hymson directly via the company’s contact avenues.

Conclusion

Vascarta's receipt of Orphan Drug Designation for Vasceptor® is a beacon of hope for many suffering from Sickle Cell Disease. With promising preclinical results and a clear focus on bringing innovative therapies to market, Vascarta is set to change the treatment landscape for this community, aiming for better health outcomes and improved patient lives.